Anticipating Financial Updates from Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a promising biotechnology company focused on cell and exosome-based therapies, is gearing up to share significant financial updates. The firm has announced that it will release its financial results for the fourth quarter and full fiscal year ending December 31, 2024, on an anticipated date in March.
Key Event Details
The announcement is expected to take place following market closure on March 19, 2025. The company's management has scheduled a conference call and webcast for 4:30 p.m. ET that same day. This event will provide shareholders and interested parties with a comprehensive understanding of Capricor's financial performance and any recent corporate developments.
How to Join the Conference Call
For those interested in participating, the conference call can be accessed using the following information: it will be toll-free for U.S. callers at 1-800-717-1738, and international participants can join by dialing 1-646-307-1865. Additionally, the conference ID is 98172, making it easy for attendees to connect.
The Role of Deramiocel in Capricor's Future
At the heart of Capricor's research and development efforts is its lead product candidate, deramiocel. This innovative cell therapy has been designed to combat rare diseases such as Duchenne muscular dystrophy. Current clinical studies are promising, suggesting that deramiocel could offer significant benefits by demonstrating immunomodulatory, antifibrotic, and regenerative properties. Capricor is hopeful about deramiocel's potential to change lives and enhance the treatment landscape.
Exploring Exosome Technology
Beyond deramiocel, Capricor’s dedication to exploring advanced technologies is evident in its proprietary StealthX™ platform. This innovative approach leverages exosomes for targeted therapeutic delivery, aiming to revolutionize how diseases are treated and prevented. The potential applications encompass a broad spectrum, including vaccine development and the precise delivery of oligonucleotides and proteins.
Commitment to Advancement
Capricor Therapeutics is firmly committed to expanding its capabilities and fostering breakthrough therapies to address unmet medical needs. The ongoing support from stakeholders is essential as the company navigates the complexities of clinical trials and regulatory approvals.
Staying Informed with Follow-Up
For those unable to attend the live session, a replay of the webcast will be made available shortly after the event, ensuring that stakeholders can stay informed about Capricor's developments and financial results.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is at the forefront of biotechnological innovation. With a passionate focus on cell therapy and exosome technology, it strives to push the boundaries of medical science in the realm of rare diseases. By continually developing promising therapies like deramiocel, Capricor aims to create transformative solutions for patients in dire need of effective treatments.
Key Contact Information
For media inquiries, Capricor’s media contact is Raquel Cona at KCSA Strategic Communications. She can be reached at rcona@kcsa.com or by phone at 212.896.1204. Moreover, AJ Bergmann, the Chief Financial Officer, is available for company-related questions at abergmann@capricor.com, with a direct line at 858.727.1755.
Frequently Asked Questions
1. When will Capricor Therapeutics announce their financial results?
The financial results are scheduled to be announced after market closure on March 19, 2025.
2. How can I participate in the conference call?
You can join the call by dialing 1-800-717-1738 in the U.S. or 1-646-307-1865 internationally, using conference ID 98172.
3. What is deramiocel, and why is it important?
Deramiocel is Capricor's lead product candidate, significant for treating Duchenne muscular dystrophy through its unique cell therapy approach.
4. How is Capricor investing in exosome technology?
The company utilizes its StealthX™ platform to enhance the targeted delivery of therapies, including vaccines and proteins, marking a novel approach in treatment strategies.
5. Where can I find more information about Capricor?
Additonally, more information can be found on their official website at capricor.com.
